Compare TRIB & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIB | JSPR |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | Ireland | United States |
| Employees | N/A | 22 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 14.9M |
| IPO Year | 1996 | N/A |
| Metric | TRIB | JSPR |
|---|---|---|
| Price | $0.39 | $0.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 1.4M | 451.2K |
| Earning Date | 05-22-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.51 | N/A |
| Revenue Next Year | $13.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.32 |
| 52 Week High | $3.44 | $3.84 |
| Indicator | TRIB | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 35.90 | 48.62 |
| Support Level | $0.31 | $0.42 |
| Resistance Level | $0.75 | $0.60 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 24.21 | 70.13 |
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.